Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.
Virpax Pharmaceuticals, Inc. (symbol: VRPX) is a pioneering biopharmaceutical company dedicated to developing advanced drug delivery systems aimed at improving patient compliance and achieving therapeutic efficacy. Specializing in non-opioid pain management, Virpax is committed to enhancing patients' quality of life through innovative pharmaceutical products.
As a preclinical stage company, Virpax focuses on creating branded pharmaceutical products for pain management. Their impressive product portfolio includes:
- Topical Metered-Dose Spray: A novel approach for localized pain relief.
- Liposomal in Hydrogel Encapsulation: A cutting-edge technology designed to enhance drug delivery and efficacy.
- Enkephalin Intranasal Spray: An innovative treatment method aimed at providing rapid pain relief.
Virpax Pharmaceuticals collaborates with a network of U.S. and global partners to advance the development of its proprietary drug platforms. Their goal is to become a global leader in non-opioid pain management, creating value for investors and partners alike.
Recent achievements and current projects highlight Virpax’s commitment to innovation. These include advancing their drug candidates through preclinical stages, securing strategic partnerships, and working towards regulatory approvals.
Financially, Virpax Pharmaceuticals is focused on sustainable growth, leveraging cutting-edge technology to develop products that meet the unmet needs of pain management patients. The company’s strategic initiatives are designed to enhance shareholder value while pushing the boundaries of pharmaceutical advancements.
Stay tuned for the latest updates and exciting developments from Virpax Pharmaceuticals as they continue to make strides in the biopharmaceutical industry.
Virpax Pharmaceuticals has completed all FDA-required pre-clinical studies for its investigational topical analgesic, Epoladerm™, aimed at managing chronic knee pain due to osteoarthritis. The studies encompassed dermal toxicity and phototoxicity, among others. Virpax is preparing to submit its Investigational New Drug Application (IND) including these results. A clinical trial agreement with Altasciences is in place for a first-in-human pilot study in Canada, with patient enrollment expected in 2022.
Management expresses confidence that Epoladerm will be a more effective treatment option for osteoarthritis pain.
Nanomerics Ltd announced a milestone payment following the expansion of its anti-viral spray license for AnQlar™ to Virpax Pharmaceuticals (NASDAQ:VRPX). The agreement now includes worldwide rights, and the deal features an upfront payment with future revenue sharing. This funding will support Nanomerics' growth and clinical programs. CEO expressed satisfaction with the partnership aimed at developing AnQlar™ as a nasal spray to combat respiratory viruses, including SARS-CoV-2 variants.
Virpax Pharmaceuticals (NASDAQ: VRPX) has expanded its exclusive licensing agreement for AnQlar™ with Nanomerics Ltd., securing worldwide rights for development and commercialization. AnQlar has shown antiviral activity against SARS-CoV-2 and influenza in preclinical studies, inhibiting viral replication without adverse effects. Virpax aims for Investigational New Drug (IND) studies completion by Q4 2022 and plans to pursue a nonprescription drug approval pathway. Enhanced global rights are expected to strengthen strategic opportunities for AnQlar.
Virpax Pharmaceuticals (NASDAQ: VRPX) has gained media attention for its potential solutions to the opioid epidemic and COVID-19. The focus is on several non-addictive drug candidates: AnQlar™, an intranasal antiviral; Epoladerm™, targeting osteoarthritis pain; Probudur™, a long-acting anesthetic for post-surgical pain; and Envelta™, for cancer-related pain. CEO Anthony Mack shared insights on the opioid crisis, while Dr. Sheila Mathias, Chief Scientific Officer, discussed the company's product portfolio in interviews.
Virpax Pharmaceuticals (NASDAQ: VRPX) reported promising preclinical data on Envelta (NES100), an intranasal enkephalin spray designed for pain management in acute and chronic cases. Studies indicate Envelta is well-tolerated with no adverse findings in toxicity assessments conducted by the NIH. The company is focused on submitting an IND to the FDA to initiate Phase 1 trials, aiming to support its potential as a non-addictive treatment for cancer pain and PTSD.
Virpax Pharmaceuticals (NASDAQ: VRPX) has selected Altasciences to conduct a first-in-human study of Epoladerm™ for chronic knee pain due to osteoarthritis. This innovative treatment utilizes a pre-filled device for a convenient topical spray application. Set to begin in Q2 2022 at Altasciences’ Montreal facility, the study aims to support the FDA's 505(b)(2) approval pathway. Altasciences, experienced in clinical trials, is committed to advancing this analgesic therapy towards regulatory approval, enhancing patient care through its cutting-edge technology.
Virpax Pharmaceuticals (NASDAQ: VRPX) announced positive results from four preclinical dermal safety studies for its investigational product, Epoladerm (diclofenac epolamine), aimed at managing osteoarthritis knee pain. Conducted by Charles River Laboratories, these studies indicated that Epoladerm was well-tolerated with no serious adverse findings, including skin irritation or sensitization. The successful outcomes support the company’s upcoming Investigational New Drug Application, paving the way for first-in-human trials.
Virpax Pharmaceuticals will present virtually at the H.C. Wainwright BioConnect Virtual Conference from January 10 to January 13, starting at 7:00 a.m. ET. CEO
Virpax Pharmaceuticals (NASDAQ: VRPX) has made notable strides in its product pipeline as of 2021. The company anticipates starting initial human trials for Epoladerm in Q2 2022. Key advancements include the development of AnQlar, an OTC antiviral candidate, and VRP324, a CBD formulation for epilepsy. Additionally, Virpax appointed new board members and raised approximately $58 million from IPOs, enhancing its R&D funding. Epoladerm’s toxicology study showed it was well-tolerated in minipigs. The company intends to conduct Phase 1 studies for Epoladerm in Canada soon.
Virpax Pharmaceuticals (NASDAQ: VRPX) has entered into a clinical trial agreement with Altasciences for a First in Human study of Epoladerm™, targeting pain associated with osteoarthritis of the knee. The trial, set to commence in Canada, aims to enroll its first patient by Q2 2022. Epoladerm™ is a topical spray film designed to provide a non-addictive solution for chronic pain. The data generated will support regulatory filings for FDA approval under the 505(b)(2) pathway, enhancing Virpax's portfolio for non-addictive pain management.
FAQ
What is the current stock price of Virpax Pharmaceuticals (VRPX)?
What is the market cap of Virpax Pharmaceuticals (VRPX)?
What does Virpax Pharmaceuticals, Inc. specialize in?
What are some of Virpax Pharmaceuticals' key products?
Is Virpax Pharmaceuticals a preclinical stage company?
What is Virpax's goal in the pharmaceutical industry?
How does Virpax enhance the efficacy of its products?
Who does Virpax collaborate with for its developments?
What type of spray is included in Virpax's product portfolio?
How is Virpax Pharmaceuticals enhancing shareholder value?
What technology does Virpax use for drug encapsulation?
Where can I find the latest news about Virpax Pharmaceuticals?
